NCT06210815View on ClinicalTrials.gov

A Study of HLX42 in Advanced/Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

March 14, 2024

Primary Completion Date

September 2, 2026

Study Completion Date

June 14, 2027

Conditions
Solid Tumor and NSCLC
Interventions
DRUG

HLX42

HLX42 is an anti-EGFR monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

Trial Locations (1)

Unknown

RECRUITING

Guangdong Provincial People's Hospital, Guangdong

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY